Endogenous Opioid Modulation by Ketamine

Demonstrate the acute effects of ketamine on endogenous µ-opioid neurotransmission in humans.

Topic Depression
Compound Placebo Ketamine
Country United States of America
Visit trial
Status Withdrawn
Results Published
Start date 08 January 2019
End date 08 January 2019
Phase Phase III
Design Blinded
Type Interventional
Generation First
Participants 0
Sex All
Age 18- 65
Therapy No

Trial Details

This study will test the hypothesis that the rapidly-acting antidepressant ketamine improves core depressive symptoms by acutely activating the brain's endogenous µ-opioid system.

Trial Number NCT03051945

Sponsors & Collaborators

University of Wisconsin-Madison
The Transdisciplinary Center for Research in Psychoactive Substances (TCRPS) was launched at the University of Wisconsin-Madison in 2021.

Measures Used

Hamilton Depression Rating Scale
The Hamilton Depression Rating Scale (HDRS) is a multiple item questionnaire used to provide an indication of depression, and as a guide to evaluating recovery. The scale consists of 17 items which each item being scoring on a 3 or 5 point scale. The higher the score, the more likely a person is depressed.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.